Update on the immunology of UV and visible radiation therapy: phototherapy, photochemotherapy and photodynamic therapy

References

• Krutmann J, Morita A. Mechanisms of ultraviolet (UV) B and UVA phototherapy. J. Investig. Dermatol. Symp. Proc.4(1), 70–72 (1999).
   PubMedGoogle Scholar
• Hanneman KK, Cooper KD, Baron ED. Ultraviolet immunosuppression: mechanisms and consequences. Dermatol. Clin.24(1), 19–25 (2006).
   PubMedGoogle Scholar
• Cooper KD, Baron ED, Matsui MS. Implications of UV-induced inflammation and immunomodulation. Cutis72(3 Suppl.), 11–16 (2003).
   Google Scholar
• Granstein RD, Matsui MS. UV radiation-induced immunosuppression and skin cancer. Cutis74(5 Suppl.), 4–9 (2004).
   PubMed Web of Science ®Google Scholar
• Dumay O, Karam A, Vian L et al. Ultraviolet AI exposure of human skin results in langerhans cell depletion and reduction of epidermal antigen-presenting cell function: partial protection by a broad- spectrum sunscreen. Br. J. Dermatol.144(6), 1161–1168 (2001).
   PubMed Web of Science ®Google Scholar
• Garssen J, van Loveren H. Effects of ultraviolet exposure on the immune system. Crit. Rev. Immunol.21(4), 359–397 (2001).
   PubMed Web of Science ®Google Scholar
• Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol.2(212), 965–972 (2002).
   PubMed Web of Science ®Google Scholar
• Bennett CL, van Rijn E, Jung S et al. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J. Cell Biol.169(4), 569–576 (2005).
   PubMed Web of Science ®Google Scholar
• Kissenpfennig A, Henri S, Dubois B et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity22(5), 643–654 (2005).
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ. Epidermal Langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity.23(6), 611–620 (2005).
   PubMed Web of Science ®Google Scholar
• Berneburg M, Krutmann J. Photoimmunology, DNA repair and photocarcinogenesis. J. Photochem. Photobiol. B, Biol.54(2–3), 87–93 (2000).
   PubMedGoogle Scholar
• De Rie MA, Bos JD. Photo(chemo)therapeutic modulation of the skin immune system. In: Skin Immune System. Bos JD (Ed.). CRC Press, FL, USA 771–788 (2005).
   Google Scholar
• Schmitt DA, Owen-Schaub L, Ullrich SE. Effect of IL-12 on immune suppression and suppressor cell induction by ultraviolet radiation. J. Immunol.154(10), 5114–5120 (1995).
   PubMed Web of Science ®Google Scholar
• Ullrich SE. The role of epidermal cytokines in the generation of cutaneous immune reactions and ultraviolet radiation-induced immune suppression. Photochem. Photobiol.62(3), 389–401(1995).
   PubMed Web of Science ®Google Scholar
• Kimber I, Cumberbatch M, Dearman RJ, Bhushan M, Griffiths CE. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br. J. Dermatol.142(3), 401–412 (2000).
   PubMed Web of Science ®Google Scholar
• Schwarz A, Bhardwaj R, Aragane Y et al. Ultraviolet-B-induced apoptosis of keratinocytes: evidence for partial involvement of tumor necrosis factor-α in the formation of sunburn cells. J. Invest. Dermatol.104(6), 922–927 (1995).
   PubMed Web of Science ®Google Scholar
• Wlaschek M, Heinen G, Poswig A, Schwarz A, Krieg T, Scharffetter-Kochanek K. UVA-induced autocrine stimulation of fibroblast-derived collagenase/MMP-1 by interrelated loops of interleukin-1 and interleukin-6. Photochem. Photobiol.59(5), 550–556 (1994).
   PubMed Web of Science ®Google Scholar
• Stege H, Berneburg M, Humke S et al. High-dose UVA1 radiation therapy for localized scleroderma. J. Am. Acad. Dermatol.36(6 Pt 1), 938–944 (1997).
   PubMed Web of Science ®Google Scholar
• Grewe M, Klammer M, Stege H, Krutmann J. Involvement of direct and indirect mechanisms in ultraviolet B radiation (UVBR)-induced inhibition of ICAM-1 expression in human antigen presenting cells. J. Invest. Dermatol.106(4), 933 (1996).
   Google Scholar
• Godar DE. UVA1 radiation triggers two different final apoptotic pathways. J. Invest. Dermatol.112(1), 3–12 (1999).
   PubMed Web of Science ®Google Scholar
• Schwarz A, Beissert S, Grosse-Heitmeyer K et al. Evidence for functional relevance of CTLA-4 in ultraviolet-radiation-induced tolerance. J. Immunol.165(4), 1824–1831 (2000).
   PubMed Web of Science ®Google Scholar
• Schwarz A, Maeda A, Wild MK et al. Ultraviolet radiation-induced regulatory T cells not only inhibit the induction but can suppress the effector phase of contact hypersensitivity. J. Immunol.172(2), 1036–1043 (2004).
   PubMed Web of Science ®Google Scholar
• Aragane Y, Maeda A, Schwarz A, Tezuka T, Ariizumi K, Schwarz T. Involvement of dectin-2 in ultraviolet radiation-induced tolerance. J. Immunol.171(7), 3801–3807 (2003).
   Google Scholar
• Moodycliffe AM, Ngheim D, Clydesdale G, Ullrich SE. Immune suppression and skin cancer development: regulation by NKT cells. Nat. Immunol.1(6), 521–525 (2000).
   PubMed Web of Science ®Google Scholar
• Böhm M, Luger TA, Schneider M, Schwarz T, Kuhn A. New insight into immunosuppression and treatment of autoimmune diseases. Clin. Exp. Rheumatol.24(1 Suppl. 40), S67–S71 (2006).
   Google Scholar
• Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol.3(3), 199–210 (2003).
   PubMed Web of Science ®Google Scholar
• Zheng SG, Wang JH, Koss MN, Quismorio F Jr, Gray JD, Horwitz DA. CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-β suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J. Immunol.172, 1531–1539 (2004).
   PubMed Web of Science ®Google Scholar
• Yamauchi R, Morita A, Yasuda Y et al. Different susceptibility of malignant versus nonmalignant human T cells toward ultraviolet A-1 radiation-induced apoptosis. J. Invest. Dermatol.122(2), 477–483 (2004).
   PubMed Web of Science ®Google Scholar
• Hill LL, Ouhtit A, Loughlin SM, Kripke ML, Ananthaswamy HN, Owen-Schaub LB. Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science285(5429), 898–900 (1999).
   PubMed Web of Science ®Google Scholar
• Morita A, Werfel T, Stege H et al. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J. Exp. Med.186(10), 1763–1768 (1997).
   PubMedGoogle Scholar
• Burren R, Scaletta C, Frenk E, Panizzon RG, Applegate LA. Sunlight and carcinogenesis : expression of p53 and pyrimidine dimers in human skin following UVA I, UVA I + II and solar simulating radiations. Int. J. Cancer76(2), 201–206 (1998).
   PubMed Web of Science ®Google Scholar
• Katiyar SK, Matsui MS, Mukhtar H. Kinetics of UV light-induced cyclobutane pyrimidine dimers in human skin in vivo: an immunohistochemical analysis of both epidermis and dermis.Photochem. Photobiol.72(6), 788–793 (2000).
   PubMed Web of Science ®Google Scholar
• Sheehan JM, Cragg N, Chadwick CA, Potten CS, Young AR. Repeated ultraviolet exposure affords the same protection against DNA photodamage and erythema in human skin types II and IV but is associated with faster DNA repair in skin type IV. J. Invest. Dermatol.118(5), 825–829 (2002).
   PubMed Web of Science ®Google Scholar
• Vink AA, Strickland FM, Bucana C et al. Localization of DNA damage and its role in altered antigen-presenting cell function in ultraviolet-irradiated mice. J. Exp. Med.183(4), 1491–1500 (1996).
   PubMed Web of Science ®Google Scholar
• Abboussekhra A, Biggerstaff M, Shivji MK et al. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell80(6), 859–868 (1995).
   Google Scholar
• Petit-Frere C, Clingen PH, Grewe M et al. Induction of interleukin-6 production by ultraviolet radiation in normal human epidermal keratinocytes and in a human keratinocyte cell line is mediated by DNA damage. J. Immunol.111(3), 354–359 (1998).
   Google Scholar
• O’Connor A, Nishigori C, Yarosh D et al. DNA double strand breaks in epidermal cells cause immune suppression in vivo and cytokine production in vitro. J. Immunol.157(1), 271–278 (1996).
   PubMed Web of Science ®Google Scholar
• Kammeyer A, Teunissen MB, Pavel S, de Rie MA, Bos JD. Photoisomerization spectrum of urocanic acid in human skin and in vitro: effects of simulated solar and artificial ultraviolet radiation. Br. J. Dermatol.132(6), 884–891 (1995).
   PubMed Web of Science ®Google Scholar
• Walterscheid JP, Nghiem DX, Kazimi N et al. Cis-urocanic acid, a sunlight-induced immunosuppressive factor, activates immune suppression via the 5-HT2A receptor. Proc. Natl Acad. Sci. USA103(46), 17420–17425 (2006).
   Google Scholar
• Kielbassa C, Roza L, Epe B. Wavelength dependence of oxidative DNA damage induced by UV and visible light. Carcinogenesis18(4), 811–816 (1997).
   PubMed Web of Science ®Google Scholar
• Nakamura T, Pinnell SR, Darr D et al. Vitamin C abrogates the deleterious effect of UVB radiation on cutaneous immunity by a mechanism that does not depend on TNF. J. Invest. Dermatol.109(1), 20–24 (1997).
   Google Scholar
• Weichenthal M, Schwarz T. Phototherapy: how does UV work? Photodermatol. Photoimmunol. Photomed.21(5), 260–266 (2005).
   PubMed Web of Science ®Google Scholar
• Ständer H, Schiller M, Schwarz T et al. UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J. Am. Acad. Dermatol.46, 799–800 (2002).
   Google Scholar
• Alard P, Niizeki H, Hanninen L et al. Local ultraviolet B irradiation impairs contact hypersensitivity induction by triggering release of tumor necrosis factor-α from mast cells. Involvement of mast cells and Langerhans cells in susceptibility to ultraviolet B.J. Invest. Dermatol.113(6), 983–990 (1999).
   Google Scholar
• Garrsen J, Buckley TL, van Loveren H. A role for neuropeptides in UVB-induced systemic immunosuppression. Photochem. Photobiol.68(2), 205–210 (1998).
   Google Scholar
• Fischer T, Alsins J, Berne B. Ultraviolet action spectrum and evaluation of ultraviolet lamps for psoriasis healing. Br. J. Dermatol.23(10), 633–637 (1984).
   Google Scholar
• Guckian M, Jones CD, Vestey JP et al. Immunomodulation at the initiation of phototherapy and photochemotherapy. Photodermatol. Photoimmunol. Photomed.11(4), 163–169 (1995).
   PubMedGoogle Scholar
• El-Ghorr AA, Norval M. Biological effects of narrow-band (311 nm TL01) UVB irradiation: a review. Photochem. Photobiol.38(2–3), 99–106 (1997).
   Google Scholar
• Krutmann J, Morita A. Therapeutic photomedicine: phototherapy. In: Fitzpatrick’s Dermatology in General Medicine. Freedberg IM, Eisen AZ, Wolff K et al. (Eds). McGraw-Hill, NY, USA 2469–2476 (2003).
   Google Scholar
• Krueger JG, Wolfe JT, Nabeja RT et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J. Exp. Med.182(6), 2057–2068 (1995).
   PubMed Web of Science ®Google Scholar
• Ozawa M, Ferenczi K, Kikuchi T et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J. Exp. Med.189(4), 711–718 (1999).
   PubMed Web of Science ®Google Scholar
• Dawe RS. A quantitative review of studies comparing the efficacy of narrow-band and broad-band ultraviolet B for psoriasis. Br. J. Dermatol.149(3), 669–672 (2003).
   PubMed Web of Science ®Google Scholar
• Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomized controlled trial. Lancet357, 2012–2016 (2001).
   PubMed Web of Science ®Google Scholar
• Der-Petrossian M, Seeber A, Hönigsmann H et al. Half-side comparison study on the efficacy of 8-methoxypsoralen bath–PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. Br. J. Dermatol.142(1), 39–43 (2000).
   PubMedGoogle Scholar
• Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J. Am. Acad. Dermatol.56(2), 274–278 (2007).
   PubMed Web of Science ®Google Scholar
• Tjioe M, Gerritsen MJP, Juhlin L, van de Kerkhof PC. Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm. Venereol.82(5), 369–372 (2002).
   PubMed Web of Science ®Google Scholar
• Njoo D, Westerhof W. Vitiligo . Pathogenesis and treatment. Am. J. Clin. Dermatol.2, 167–181 (2001).
   PubMedGoogle Scholar
• Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment of vitiligo. J. Am. Acad. Dermatol.44(6), 999–1003 (2001).
   PubMed Web of Science ®Google Scholar
• Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br. J. Dermatol.146(2), 178–188 (2002).
   PubMed Web of Science ®Google Scholar
• Clark C, Dawe RS, Evans AT, Lowe G, Ferguson J. Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch. Dermatol.136(6), 748–752 (2000).
   PubMed Web of Science ®Google Scholar
• Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311 nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch. Dermatol.135, 1377–1380 (1999).
   PubMed Web of Science ®Google Scholar
• Diederen PV, van Weelden H, Sanders CJ, Toonstra J, van Vloten WA. Narrowband UVB and psoralen-UVA in the treatment of early -stage mycosis fungoides: a retrospective study. J. Am. Acad. Dermatol.48(2), 215–219 (2003).
   PubMed Web of Science ®Google Scholar
• Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur. J. Cancer42(8), 1014–1030 (2006).
   PubMed Web of Science ®Google Scholar
• Ibbotson SH, Bilsland D, Cox NH et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br. J. Dermatol.151(2), 283–297 (2004).
   PubMed Web of Science ®Google Scholar
• Mang R, Krutmann J. UVA-1 phototherapy . Photodermatol. Photoimmunol. Photomed.21(2), 103–108 (2005).
   PubMedGoogle Scholar
• Plettenberg H, Stege H, Megahed M et al. Ultraviolet A1 (340–400 nm) phototherapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol.41(1), 47–50 (1999).
   Google Scholar
• Zane C, Leali C, Airo P, De Panfilis G, Pinton PC. “High-dose” UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides. J. Am. Acad. Dermatol.44(4), 629–633 (2001).
   PubMed Web of Science ®Google Scholar
• von Kobyletzki G, Dirschka T, Freitag M, Hoffman K, Altmeyer P. Ultraviolet-A1 phototherapy improves the status of the skin in cutaneous T-cell lymphoma. Br. J. Dermatol.140(4), 768–769 (1999).
   Google Scholar
• Gobello T, Mazzanti C, Sordi D et al. Medium-versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study. J. Am. Acad. Dermatol.49(4), 679–684 (2003).
   PubMed Web of Science ®Google Scholar
• Stege H, Schöpf E, Ruzicka T, Krutmann J. High-dose UVA1 for urticaria pigmentosa. Lancet347(8993), 64 (1996).
   PubMed Web of Science ®Google Scholar
• Morita A, Kobayashi K, Isomura I et al. Ultraviolet A1 (340–400 nm) phototherapy for scleroderma in systemic sclerosis. J. Am. Acad. Dermatol.43, 670–674 (2000).
   PubMed Web of Science ®Google Scholar
• Grundmann-Kollmann M, Behrens S, Gruss C, Gottlöber P, Peter RU, Kerscher M. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J. Am. Acad. Dermatol.42(1 Pt 1), 134–136 (2000).
   PubMedGoogle Scholar
• Polderman MC, Govaert JC, Le Cessie S, Pavel S. A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema. Clin. Exp. Dermatol.28(6), 584–587 (2003).
   PubMed Web of Science ®Google Scholar
• Petering H, Breuer C, Herbst R, Kapp A, Werfel T. Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J. Am. Acad. Dermatol.50(1), 68–72 (2004).
   PubMed Web of Science ®Google Scholar
• von Kobyletzki G, Kreuter JA, Nordmeier R, Stücker M, Altmeyer P. Treatment of idiopathic mucinosis follicularis with UVA1 cold light phototherapy. Dermatology201(1), 76–77 (2000).
   PubMed Web of Science ®Google Scholar
• Pinton PC, Capezzera R, Zane C, De Panfilis G. Medium-dose ultraviolet A1 therapy for pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica. J. Am. Acad. Dermatol.47(3), 410–414 (2002).
   PubMed Web of Science ®Google Scholar
• Herbst RA, Vogelbruch M, Ehnis A, Kiehl P, Kapp A, Weiss J. Combined ultraviolet A1 radiation and acitretin therapy as a treatment option for pityriasis rubra pilaris. Br. J. Dermatol.142(3), 574–575 (2000).
   Google Scholar
• Muchenberger S, Schöpf E, Simon JC. Phototherapy with UV-A-I for generalized granuloma annulare. Arch. Dermatol.133, 1605 (1997).
   Google Scholar
• Grabbe J, Welker P, Humke S et al. High-dose ultraviolet A1 (UVA1), but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema. J. Invest. Dermatol.107(3), 419–422 (1996).
   PubMed Web of Science ®Google Scholar
• Laskin JD, Lee E, Yurkow EJ, Gallo MA. A possible mechanism of psoralen phototoxicity not involving direct interaction with DNA. Proc. Natl Acad. Sci. USA82(18), 6158–6162 (1985).
   PubMed Web of Science ®Google Scholar
• Averbeck D. Recent advances in psoralen phototoxicity mechanism. Photochem. Photobiol.50(6), 859–882 (1989).
   PubMed Web of Science ®Google Scholar
• Hönigsmann H. Phototherapy for psoriasis. Clin. Exp. Dermatol.26(4), 343–350 (2001).
   PubMed Web of Science ®Google Scholar
• Gordon PM, Diffey BL, Matthews JNS, Farr PM. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J. Am. Acad. Dermatol.41(5 Pt 1), 728–732 (1999).
   PubMed Web of Science ®Google Scholar
• Tanew A, Radakovic-Fijan S, Schemper M, Hönigsmann H. Narrowband UV-B phototherapy vs. photochemotherapy in the treatment of chronic plaque-type psoriasis. Arch. Dermatol.135(5), 519–524 (1999).
   PubMedGoogle Scholar
• Efferth T, Fabry U, Osieka R. Induction of apoptosis, depletion of glutathione, and DNA damage by extracorporeal photochemotherapy and psoralen with exposure to UV light in vitro. Anticancer Res.21(4A), 2777–2783 (2001).
   Google Scholar
• Cox NH, Turbitt ML, Ashworth J, Mackie RM. Distribution of T cell subsets and Langerhans cells in mycosis fungoides, and the effect of PUVA therapy. Clin. Exp. Dermatol.11(6), 564–568 (1986).
   Google Scholar
• Okamolo H, Takigawea M, Horio T. Alteration of lymphocyte functions by 8-methoxypsoralen and longwave ultraviolet radiation: suppressive effects of PUVA on T-lymphocyte migration in vitro. J. Invest. Dermatol.84(3), 203–205 (1985).
   Google Scholar
• Hawk JL, Le Grice P. The efficacy of localized PUVA therapy for chronic hand and foot dermatoses. Clin. Exp. Dermatol.19(6), 479–482 (1994).
   Google Scholar
• Schempp CM, Muller H, Czech W et al. Treatment of chronic palmoplantar eczema with local bath–PUVA therapy. J. Am. Acad. Dermatol.36(5 Pt 1), 733–737 (1997).
   PubMedGoogle Scholar
• Sheehan-Dare RA, Goodfield MJ, Rowell NR. Topical psoralen photochemotherapy (PUVA) and superficial radiotherapy in the treatment of chronic hand eczema. Br. J. Dermatol.121(1), 65–69 (1989).
   PubMed Web of Science ®Google Scholar
• British Photodermatology Group guidelines for PUVA. Br. J. Dermatol.130(2), 246–255 (1994).
   PubMed Web of Science ®Google Scholar
• Halpern SM, Anstey AV, Dawe RS et al. Guidelines for topical PUVA: a report of a workshop of the British Photodermatology Group. Br. J. Dermatol.142(1), 22–31 (2000).
   PubMed Web of Science ®Google Scholar
• Morison WL, Baughman RD, Day RM et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch. Dermatol.134(5), 595–598 (1998).
   PubMed Web of Science ®Google Scholar
• Enomoto DN, Schellekens PT, Yong SL, ten Berge IJ, Mekkes JR, Bos JD. Extracorporeal photochemotherapy (photopheresis) induces apoptosis in lymphocytes: a possible mechanism of action of PUVA therapy. Photochem. Photobiol.65(1), 177–180 (1997).
   PubMed Web of Science ®Google Scholar
• Maeda A, Schwarz A, Kernebeck K et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J. Immunol.174(10), 5968–5976 (2005).
   PubMed Web of Science ®Google Scholar
• Bladon J, Tylor PC. Extracorporeal photopheresis: a focus on apoptosis and cytokines. J. Dermatol. Sci.43(2), 85–94 (2006).
   PubMed Web of Science ®Google Scholar
• Berger CL, Xu A-L, Hanlon D et al. Induction of human tumor-loaded dendritic cells. Int. J. Cancer91(4), 438–447 (2001).
   PubMed Web of Science ®Google Scholar
• Richardson SK, McGinnis KS, Shapiro M et al. Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma. J. Cutan. Med. Surg.7(4 Suppl.), 8–12 (2003).
   PubMedGoogle Scholar
• Rook AH, Suchin KR, Kao DM et al. Photopheresis: clinical applications and mechanism of action. J. Investig. Dermatol. Symp. Proc.4(1), 85–90 (1999).
   PubMed Web of Science ®Google Scholar
• McKenna KE, Whittaker S, Rhodes LE et al. Evidence-based practice of photopheresis 1987–2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma group. Br. J. Dermatol.154(1), 7–20 (2006).
   PubMed Web of Science ®Google Scholar
• Heald P, Rook M, Perez M et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J. Am. Acad. Dermatol.27(3), 427–433 (1992).
   PubMed Web of Science ®Google Scholar
• Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N. Engl. J. Med.316(6), 297–303 (1987).
   PubMed Web of Science ®Google Scholar
• Vonderheid EC. Photopheresis: current and future perspectives. J. Cutan. Med. Surg.7(4 Suppl.), 1–2 (2003).
   Google Scholar
• Di Renzo M, Rubegni P, De Aloe G et al. Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T cell lymphoma. Immunology92(1), 99–103 (1997).
   PubMed Web of Science ®Google Scholar
• Alcindor T, Gorgun G, Miller KB et al. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood98(5), 1622–1625 (2001).
   PubMed Web of Science ®Google Scholar
• Foss FM. Extracorporeal photopheresis in the treatment of graft-vs-host disease. J. Cutan. Med. Surg.7(4 Suppl.), S13–S17 (2003).
   PubMedGoogle Scholar
• Child FJ, Ratnavel R, Watkins P et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant.23(9), 881–887 (1999).
   PubMed Web of Science ®Google Scholar
• Greinix HT, Volc–Platzer B, Rabitsch W et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood92(9), 3098–3104 (1998).
   PubMed Web of Science ®Google Scholar
• Sharman W, Allen C, Van Lier J. Photodynamic therapeutics basic principles and clinical applications. Drug Discov. Today4(11), 507–517 (1999).
   PubMed Web of Science ®Google Scholar
• Gold M, Goldman M. 5-aminolevulinic acid photodynamic therapy: where we have been and where we are going. Dermatol. Surg.30(8), 1077–1084 (2004).
   PubMed Web of Science ®Google Scholar
• Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem. Photobiol. Sci.1, 1–21 (2002).
   PubMed Web of Science ®Google Scholar
• Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer6(7), 535–543 (2006).
   PubMed Web of Science ®Google Scholar
• Stapleton M, Rhodes LE. Photosensitizers for photodynamic therapy for cutaneous disease. J. Dermatol. Treat.14(2), 107–112 (2003).
   PubMedGoogle Scholar
• Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol.5(8), 497–508 (2004).
   PubMed Web of Science ®Google Scholar
• Grebenova D, Cajthamlova H, Bartosova J et al. Selective destruction of leukaemic cells by photoactivation of 5-aminolaevulinic acid-induced protoporphyrin-IX. J. Photochem. Photobiol. B47(1), 74–81(1998).
   Google Scholar
• Boehncke WH, Ruck A, Naumann J, Sterry W, Kaufmann R. Comparison of sensitivity towards photodynamic therapy of cutaneous resident and infiltrating cell types in vitro. Lasers Surg. Med.19(4), 451–457 (1996).
   Google Scholar
• Gold MH. Photodynamic therapy in dermatology: the next five years. Dermatol. Clin.25(1), 119–120 (2007).
   Google Scholar
• Gold MH. Introduction to photodynamic therapy: early experience. Dermatol. Clin.25(1), 1–4 (2007).
   Google Scholar
• Bablias P, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology. Eur. J. Dermatol.16(4), 340–348 (2006).
   Google Scholar
• Fijan S, Hönigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using δ-aminolaevulinic acid and desferrioxamine. Br. J. Dermatol.133(2), 282–288 (1995).
   PubMed Web of Science ®Google Scholar
• Zeitouni NC, Shieh S, Oseroff AR. Laser and photodynamic therapy in the management of cutaneous malignancies. Clin. Dermatol.19(3), 328–338 (2001).
   PubMed Web of Science ®Google Scholar
• Cox NH, Eedy DJ, Morton CA; Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists. Guidelines for management of Bowen’s disease: 2006 update. Br. J. Dermatol.156(1), 11–21 (2007).
   PubMed Web of Science ®Google Scholar
• Morton CA. 5-ALA matches 5-FU in Tx of Bowen’s disease. Dermatol. Times21, 23 (2000).
   Google Scholar
• Braathen LR, Szeimies RM, Basset-Seguin N et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J. Am. Acad. Dermatol.56(1), 125–143 (2007).
   PubMed Web of Science ®Google Scholar
• Lui H, Salasche S, Kollias N et al. Photodynamic therapy of nonmelanoma skin cancer with topical aminolevulinic acid: a clinical and histologic study. Arch. Dermatol.131(6), 737–738 (1995).
   PubMedGoogle Scholar
• Kubler AC, Haase T, Staff C, Kahle B, Rheinwald M, Muhling J. Photodynamic therapy of primary nonmelanomatous skin tumours of the head and neck. Lasers Surg. Med.25(1), 60–68 (1999).
   PubMed Web of Science ®Google Scholar
• Taub AF. Photodynamic therapy: other uses. Dermatol. Clin.25(1), 101–109 (2007).
   Google Scholar
• Fritsch C, Goerz G, Ruzicka T. Photodynamic therapy in dermatology. Arch. Dermatol.134(2), 207–214 (1998).
   PubMed Web of Science ®Google Scholar
• Nootheti PK, Goldman MP. Aminolevulinic acid-photodynamic therapy for rejuvenation. Dermatol. Clin.25(1), 35–45 (2007).
   PubMed Web of Science ®Google Scholar
• Touma DJ, Gilchrest BA. Topical photodynamic therapy : a new tool in cosmetic dermatology. Semin. Cutan. Med. Surg.22(2), 124–130 (2003).
   PubMed Web of Science ®Google Scholar
• Goldman MP, Boyce SM. A single - center study of aminolevulinic acid and 417 nm photodynamic therapy in the treatment of moderate to severe acne vulgaris. J. Drugs Dermatol.2(4), 393–396 (2003).
   PubMedGoogle Scholar
• Hongcharu W, Taylor CR, Chang Y, Aghassi D, Suthamjariya K, Anderson RR. Topical ALA- photodynamic the rapy for the treatment of acne vulgaris. J. Invest. Dermatol.115(2), 183–192 (2000).
   PubMed Web of Science ®Google Scholar
• Taub AF. Photodynamic the rapy for the treatment of acne : a pilot study. J. Drugs Dermatol.3(6 Suppl.), S10–S14 (2004).
   PubMedGoogle Scholar
• Divaris DX, Kennedy JC, Pottier RH. Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence. Am. J. Pathol.136(4), 891–897 (1990).
   PubMed Web of Science ®Google Scholar
• Stender IM, Na R, Fogh H, Gludd C, Wulf HC. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet355(9208), 963–966 (2000).
   PubMed Web of Science ®Google Scholar
• Morton CA, Brown SB, Collins S et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br. J. Dermatol.146(4), 552–567 (2002).
   PubMed Web of Science ®Google Scholar
• Frank RG, Bos JD. Photodynamic therapy for condylomata acuminata with local application of 5-aminolaevulinic acid. Genitourin. Med.72(1), 70–71 (1996).
   PubMedGoogle Scholar
• Rivard J, Ozog D. Henry Ford Hospital Dermatology experience with levulan kerastick and blue light photodynamic therapy. J. Drugs Dermatol.5(6), 556–561 (2006).
   PubMedGoogle Scholar
• Gold MH, Bradshaw VL, Boring MM, Bridges TM, Biron JA, Lewis TL. Treatment of sebaceous gland hyperplasia by photodynamic therapy with 5-aminolevulinic acid and a blue light source or intense pulsed light source. J. Drugs Dermatol.3(6 Suppl.), S6–S9 (2004).
   PubMedGoogle Scholar
• Dierickx CC, Goldenhersh M, Dwyer P, Stratigos A, Mihm M, Anderson RR. Photodynamic therapy for nevus sebaceus with topical δ aminolevulinic acid. Arch. Dermatol.135(6), 637–40 (1999).
   Google Scholar
• Radakovic-Fijan S, Blecha-Thalhammer U, Schleyer V. Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study. Br. J. Dermatol.152(2), 279–283 (2005).
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Tremblay JF, Juzenas P, Boushira M, Lui H. Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques. J. Invest. Dermatol.119(1), 77–83 (2002).
   PubMed Web of Science ®Google Scholar
• Aghahosseini F, Arbabi-Kalati F, Fashtami LA, Djavid GE, Fateh M, Beitollahi JM. Methylene blue-mediated photodynamic therapy: a possible alternative treatment for oral lichen planus. Lasers Surg. Med.38(1), 33–38 (2006).
   Google Scholar
• Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm. Venereol.86(1), 25–28 (2006).
   PubMed Web of Science ®Google Scholar
• Wennberg AM, Keohane S, Lear JT et al. A multicenter, study of photodynamic therapy with methyl aminolevulinate (MAL-PDT) cream in immuno-compromised organ transplant recipients with non-melanoma skin cancer. Presented at: 10th World Congress on Cancers of the Skin, Vienna, Austria, 13–16 May, 2005.
   Google Scholar
• Itkin A, Gilchrest BA. δ-aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. Dermatol. Surg.30(7), 1054–1061 (2004).
   Google Scholar